In 2012, the US Agency for International Development-funded Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program, implemented by Management Sciences for Health, started working with the DGDA and conducted a comprehensive assessment of the DGDA’s regulatory systems and capacity. As part of the recommendations made in the assessment, SIAPS provided technical support to the DGDA to revive the national PV program and establish an Adverse Drug Reaction Monitoring (ADRM) cell. This cell, which is responsible for collecting adverse event reports from health care facilities, hospitals, and pharmaceutical companies, maintains and analyzes adverse event databases, including data entry and quality assurance, and shares adverse event information with WHO’s International Drug Monitoring Center (WHO-UMC) at Uppsala.
